Supernus Pharmaceuticals Inc (SUPN) Stock Analysis

Supernus Pharmaceuticals Inc (SUPN) is a publicly traded company in the HEALTHCARE sector. It trades at $44.07, carries a market capitalization of $2.60B. This page summarizes the public market data, fundamentals, and frequently asked questions for SUPN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $44.07
• Market Cap: $2.60B
• EPS: $-0.51
• 52-Week High: $59.68
• 52-Week Low: $30.83

Market Sentiment

Supernus Pharmaceuticals Inc currently has a Bullish sentiment score of 0.21.

About Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system disorders, particularly in the United States. Based in Rockville, Maryland, Supernus specializes in addressing unmet medical needs in epilepsy and migraine, supported by a promising pipeline aimed at improving patient outcomes. With a commitment to enhancing quality of life for affected individuals, the company operates in a rapidly e...

GNG Research Analysis

GNG Research scores Supernus Pharmaceuticals Inc (SUPN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for SUPN.

Frequently Asked Questions

Does SUPN pay dividends?

Supernus Pharmaceuticals Inc (SUPN) does not currently pay a regular dividend.

What is SUPN's market cap?

Supernus Pharmaceuticals Inc (SUPN) has a market capitalization of $2.60B with a current stock price of $44.07.